angiotensin IV is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Cold Stone has entered into partnerships with other companies to promote brand name products inside its stores. The first major partnership the company entered into was with Kraft Foods for its Jell-O brand in 2009. Cold Stone introduced a series of flavors of ice cream based on popular Jell-O pudding flavors; Chocolate, Butterscotch, Banana, and Vanilla. Because the pudding additives cause the ice cream to gel, it was recently noted that these flavors do not melt. Externally, a 2008 licensing agreement with Jelly Belly had a line of jelly beans flavored like some of Cold Stone's most popular ice cream flavors.
=== Season 2 === While Daemon is in Harrenhal, he sees Viserys in a hallucination that resembles the argument they had before Viserys exiled him for the first time. Viserys appears before Daemon in another vision weeks later, where Viserys tells Daemon that he never truly wanted the crown, and that the responsibility of ruling of the realm crushes a king internally. He asks Daemon if he still wants the crown, influencing Daemon's later decision to swear fealty to Rhaenyra.
The NIH Office of the Director is the central office responsible for setting policy for the NIH, and for planning, managing, and coordinating the programs and activities of all NIH components. The NIH Director plays an active role in shaping the agency's activities and outlook. The Director is responsible for providing leadership to the Institutes and Centers by identifying needs and opportunities, especially in efforts involving multiple Institutes. Within the Director's Office is the Division of Program Coordination, Planning and Strategic Initiatives with 12 divisions including:
Sources: en.wikipedia.org
16 December – The UK government orders an independent review into foreign financial interference in UK politics in response to the case of Nathan Gill, the former leader of Reform UK in Wales. The Employment Rights Bill passes its final vote in the House of Lords and will receive Royal ascent before Christmas. It is announced that former Chancellor George Osborne is to join OpenAI. 17 December – Labour grants six local authorities in and around London the power to raise larger council tax increases after reducing their share of government funding. Starmer urges Russian oligarch Roman Abramovich to honour the pledge he made to donate the £2.5bn he made from the sale of Chelsea F.C. in 2022 to victims of the Ukraine War or he will face legal proceedings. Andrea Egan is elected as general secretary of Unison, and will succeed Christina McAnea in January. Former Labour mayor Jamie Driscoll joins the Green Party. Independent MP Zarah Sultana begins a protest outside HMP Bronzefield in Surrey, where remand prisoner, who had spent over a year in prison awaiting trial, and Palestine Action member Qesser Zuhrah is on hunger strike. The protest demanded an ambulance be brought to the prison, where Zuhrar has been on hunger strike for 46 days. She was later transferred to hospital. 18 December – Christian Turner is named as the UK's new ambassador to the United States, replacing Peter Mandelson. It is announced that Nigel Farage will not face an investigation into claims Reform overspent during his 2024 election campaign.
=== Optic nerve blood supply === The optic nerve head, or prelaminar disc, primarily receives blood from the peripapillary choroidal arterioles, which stem from the elliptical anastomotic annulus connected to the circle of Zinn-Haller. The circle of Zinn-Haller is formed by branches of the lateral and posterior ciliary arteries. Beyond this region, different segments of the optic nerve are supplied by various networks of arteries and capillaries originating from the ophthalmic artery and the central retinal artery. The Zinn-Haller circle also provides blood to the thin, sieve-like section of the eye's outer layer and the optic nerve fibers within it through small, inward-facing arteries. The area just behind this layer in the optic nerve is vascularized by small returning arteries and minute blood vessels that arise from the eye's surrounding circulation and the main ophthalmic artery, interweaving through the nerve's supporting fibers. The parts of the optic nerve located within the eye socket and the canal it traverses receive blood from small arteries branching off the primary network surrounding the eye, as well as from the central retinal artery. Fluorescein angiographic studies have demonstrated that during the acute phase of NAION, there is a delay in blood flow to the optic disc, suggesting a potential impairment in the arteries directly supplying it. Other research indicates that a drop in blood pressure within specific critical areas of the optic disc's blood supply network may increase its susceptibility to damage.
=== Biosynthesis === Biosynthesis takes place in bacteria, fungi and plants, but not animals. The biosynthetic precursors to riboflavin are ribulose 5-phosphate and guanosine triphosphate. The former is converted to L-3,4-dihydroxy-2-butanone-4-phosphate. Guanosine is degraded to 4-hydroxy-2,4,5-triaminopyrimidine, which is transformed into 5-amino-6-(D-ribitylamino)uracil. These two compounds are then the substrates for the penultimate step in the pathway, catalysed by the enzyme lumazine synthase in reaction EC 2.5.1.78.
Sources: en.wikipedia.org
=== Warm temperature plants === These plants prefer to grow at temperatures of 18 °C (65 °F) to 30 °C (86 °F) Others – Begonia, Ylang Ylang – Cananga odorata, Cooktown Orchid – Dendrobium bigibbum, Tasmanian Blue Gum – Eucalyptus globulus, Poinsettia – Euphorbia pulcherima, Gladiolus – Gladiolus, Gumamela – Hibiscus rosa-sinensis, Busy Lizzie – Impatiens, Lobelia – Lobelia cardinalis, Oleander – Nerium oleander, Frangipani – Plumeria rubra, Petunia, Sampaguita – Jasminum sambac, Sturt's Desert Rose – Gossypium sturtianum, Waratah – Telopia specisissima, Royal Bluebell – Wahlenbergia gloriosa
== Precision and uncertainties == The precision to which a molar mass is known depends on the precision of the atomic masses from which it was calculated (and very slightly on the value of the molar mass constant, which depends on the measured value of the dalton). Most atomic masses are known to a precision of at least one part in ten-thousand, often much better (the atomic mass of lithium is a notable, and serious, exception). This is adequate for almost all normal uses in chemistry: it is more precise than most chemical analyses, and exceeds the purity of most laboratory reagents. The precision of atomic masses, and hence of molar masses, is limited by the knowledge of the isotopic distribution of the element. If a more accurate value of the molar mass is required, it is necessary to determine the isotopic distribution of the sample in question, which may be different from the standard distribution used to calculate the standard atomic mass. The isotopic distributions of the different elements in a sample are not necessarily independent of one another: for example, a sample which has been distilled will be enriched in the lighter isotopes of all the elements present. This complicates the calculation of the standard uncertainty in the molar mass. A useful convention for normal laboratory work is to quote molar masses to two decimal places for all calculations. This is more accurate than is usually required, but avoids rounding errors during calculations. When the molar mass is greater than 1000 g/mol, it is rarely appropriate to use more than one decimal place.
More surface area Small volume The higher the surface area and volume, the particles become stronger, more stable and durable Materials may change electrical, optical, physical, chemical, or biological properties at the nano level Makes chemical and biological reactions easier Current commercial water purifiers using nanotechnology include the LifeSaver bottle, Lifesaver Jerrycan, Lifesaver Cube, Nanoceram, and NanoH2O.
=== In humans === Xylazine is absorbed, metabolized, and eliminated rapidly. It can be inhaled or administered intravenously, intramuscularly, subcutaneously, or orally either by itself or in conjunction with other anesthetics, such as ketamine, barbiturates, chloral hydrate, and halothane in order to provide reliable anesthesia effects. The most common route of administration is injection. Xylazine's action can be seen usually 15–30 minutes after administration and the sedative effect may continue for 1–2 hours and last up to 4 hours. Once xylazine gains access to the vascular system, it is distributed within the blood, allowing it to enter the heart, lungs, liver, and kidneys. In non-fatal cases, the blood plasma concentrations range from 0.03 to 4.6 mg/L. Xylazine diffuses extensively and penetrates the blood–brain barrier, since the molecule does not have a charge and dissolves in lipids. Xylazine is metabolized by the liver's cytochrome P450 enzymes. When it reaches the liver, xylazine is metabolized and proceeds to the kidneys to be excreted in urine. Around 70% of a dose is excreted unchanged. Thus, urine can be used in detecting xylazine administration because it contains many metabolites, which are the main targets and products in urine. Within a few hours, xylazine decreases to undetectable levels. Other factors can also significantly impact the pharmacokinetics of xylazine, such as sex, nutrition, environmental conditions, and prior diseases.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.